A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
about
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneitySignatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancerHer2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer.HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slideQuantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samplesLong-term analysis to objectify the tumour grading by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) in the case of breast carcinomaHER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsExpression of glucosylceramide synthase in invasive ductal breast cancer may be correlated with high estrogen receptor status and low HER-2 statusAdvantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.The assessment of HER2 status in breast cancer: the past, the present, and the future.Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.Novel and simple method of double-detection using fluorescence in situ hybridization and fluorescence immunostaining of formalin-fixed paraffin-embedded tissue sections.HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.Diffuse invasive breast carcinoma of no special type.Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival.Highly multiplexed single-cell in situ RNA and DNA analysis with bioorthogonal cleavable fluorescent oligonucleotides.
P2860
Q27006811-BEB30275-7D34-49A7-B402-7B9E7F1CA89CQ28389284-AA80DDBA-2F4F-4270-AF83-8267122A044DQ33623561-7AE303C0-077D-4176-9A1A-82EAE1848187Q35076986-0B24B457-B99E-428A-8C14-3195A2845C5DQ35929360-7FCB05AE-95AB-46C8-83D8-C268BB44F9E9Q36261449-3FBD31B7-BCC9-435E-BEBF-36FD625EB48DQ36808502-592E1F46-0CFF-4F31-AA05-4C67F6346228Q36849324-554995FC-3D70-476E-9D87-8430C7311889Q37031799-7B38CB14-F263-4A89-A967-B0A98A334FC0Q37075632-9CAD9300-3070-4A86-9E05-57B83C64449DQ37685348-248D1F89-F6B7-46E6-BB15-3B7645CCDEE9Q38612634-F712C4A4-A115-4B33-9930-CCB6BC9F37FAQ38726662-50C73DCC-355A-4C6E-AD1C-539592EF9D24Q38802932-5F3D84FD-376F-4B4B-AC8F-465F713F1EADQ39022194-D5C0B341-12FC-41F4-B2A0-8DC991CCC300Q47965547-337BC2E4-55E0-43C8-92A9-29391C7A2D65Q49243181-34383E1E-56EE-4932-8930-8FFB16770ABEQ51175484-2E9BCD47-EC6C-459A-898D-8B92E344719CQ53293396-7645D472-5CA9-4A56-9B4D-CC7901CC16B4Q53645637-9571D3EA-0C77-4E47-BDED-94A139E931D5Q55175331-0D668845-058C-4CB5-A010-CF2E37B620D8
P2860
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A gene-protein assay for human ...... breast cancer tissue sections.
@ast
A gene-protein assay for human ...... breast cancer tissue sections.
@en
type
label
A gene-protein assay for human ...... breast cancer tissue sections.
@ast
A gene-protein assay for human ...... breast cancer tissue sections.
@en
prefLabel
A gene-protein assay for human ...... breast cancer tissue sections.
@ast
A gene-protein assay for human ...... breast cancer tissue sections.
@en
P2093
P2860
P356
P1433
P1476
A gene-protein assay for human ...... breast cancer tissue sections.
@en
P2093
Brian D Kelly
Chris Bieniarz
Hiroaki Nitta
Hitoshi Tsuda
Jim Ranger-Moore
Mary Padilla
Nikolaus Wick
Patrick Brunhoeber
Shalini Singh
P2860
P2888
P356
10.1186/1746-1596-7-60
P577
2012-05-30T00:00:00Z
P5875
P6179
1021539442